Utility of GATA‐3 in the work‐Up of breast adenocarcinoma and its differential diagnosis in serous effusions:

Hag, Mohamed El; Ha, Jennifer; Farag, Rosemary; Hag, Amani; Michael, Claire W.

doi:10.1002/dc.23521

Cited by 15 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While we believe and have previously shown that micro-arrays constructed from cell blocks are adequate to asses various markers [9,21], the limited number of cells may have resulted in lower marker sensitivity. Overall, however, our results correlate well with previously published data.…”

Section: Discussionmentioning

confidence: 76%

“…It is also expressed in a subset squamous cell carcinomas, salivary gland tumors, mesotheliomas, gynecologic carcinomas and skin adnexal tumors [5,7,8]. In spite of its multi-specific nature, GATA-3 was recently reported to have high positive predicitve value (96.2 %) in determining the breast origin in serous malignant effusion [9]. GATA-3 and estrogen receptor (ER) are involved in a cross-regulatory loop that explains initial reports correlating GATA-3 expression to ER expression; however, recent data support that GATA-3 is expressed in triple negative breast cancer and is more sensitive than the previously described markers gross cystic disease fluid protein 15 (GCDFP-15) and mammaglobin (MAM) [10,11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study

Hag

et al. 2017

Pleura and Peritoneum

Self Cite

View full text Add to dashboard Cite

Background: GATA-3 is a potential marker for detection of metastatic breast carcinoma, reportedly more sensitive than mammaglobin (MAM) and GCDFP-15. We aim to compare the sensitivity of GATA-3, MAM and GCDFP-15 in determining the breast origin of malignant effusions. Methods: Cell blocks from 27 cases of serous effusions positive for metastatic breast cancer were retrieved. Immunohistochemistry for GATA-3, MAM, gross cystic disease fluid protein 15 (GCDFP-15), estrogen receptor (ER) and progesterone receptor (PR) was performed on cell-block micro-array. Statistical analysis using two ways Chi square, one-way ANOVA and multiple regression was performed. Results: The detection rate of breast cancer in serous fluid was significantly higher with GATA-3 (88.8 %, X2 = 15.9, p = 0.00034) than with MAM (51.8 %) and GCDFP-15 (37.0 %). All ER positive cases (19) were GATA-3 positive. Conversely, all GATA-3 negative cases (3) were ER negative. The intensity of stain and percentage of positive cells were significantly higher with GATA-3 (p < 0.0001) than with MAM and GCDFP-15. The intensity and percentage of positive cells score of GATA-3 were statistically associated with ER stain intensity and percentage of positive cell scores.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study

Hag

et al. 2017

Pleura and Peritoneum

Self Cite

View full text Add to dashboard Cite

show abstract

“…Breast cancer mainly expresses ER/PR, GATA-3 and Mamma-globin, etc. The positive rate of GATA-3 is 47%-100%, which is a speci c marker of breast cancer 10 . Immunohistochemistry of the breast tumor in this patient showed positive TTF-1, NapsinA, and CK7, supporting the diagnosis of lung adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

EGFR TKI Combined with PD1 Inhibitor for EGFR Mutated Lung Cancer with Breast Metastasis

Gu¹,

Gao

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Lung adenocarcinoma with breast metastasis is rare. In the present study, a case of an advanced patient with breast metastasis from lung adenocarcinoma with EGFR 21 exon p.L858R mutation who underwent EGFR TKI combined with PD1 inhibitor is reported.Case presentation: A 62-year-old female patient diagnosed with lung adenocarcinoma who had undergone six times disease progress and breast metastasis in fifth-time disease progress.The patient underwent left breast puncture and axillary lymph node in ultrasound-guided and the postoperative pathological diagnosis of metastatic lung adenocarcinoma was confirmed. And then gene detection showed EGFR 21 exon p.L858R mutation. Breast metastasis from lung adenocarcinoma was diagnosed and the patient is being treated with Almonertinib combined with PD1 inhibitor.Conclusion: Breast metastasis is rare and lung adenocarcinoma might be the primary disease. Gene indection is important. And for lung cancer patients with recurrent pleural effusion, visit of the breast should be included in the follow-up process. In addition, the treatment model of interspersed immunotherapy after EGFR resistance has brought new ideas for the treatment of lung cancer with breast metastasis.

show abstract

“…Breast cancer mainly expresses ER/PR, GATA-3 and Mamma-globin, etc. The positive rate of GATA-3 is 47%-100%, which is a speci c marker of breast cancer 7 . Immunohistochemistry of the breast tumor in this patient showed positive TTF-1, NapsinA, and CK7, supporting the diagnosis of lung adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

Almonertinib in the treatment of lung cancer with breast metastasis: a case report

Gu¹,

Gao²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundLung adenocarcinoma with breast metastasis is rare. In the present study, a case of an advanced patient with breast metastasis from lung adenocarcinoma with EGFR 21 exon p.L858R mutation who underwent TKI-inhibitors is reported.Case presentationA 62-year-old female patient diagnosed with lung adenocarcinoma who had undergone seven times disease progress and breast metastasis in sixth time disease progress.The patient underwent left breast puncture and axillary lymph node in ultrasound-guided and the postoperative pathological diagnosis of metastatic lung adenocarcinoma was confirmed. And then gene detection showed EGFR 21 exon p.L858R mutation. Breast metastasis for lung adenocarcinoma was diagnosed and the patient are being treated with Almonertinib.ConclusionBreast metastasis is rare and lung adenocarcinoma might be the primary disease. Gene indection is important. And for lung cancer patients with recurrent pleural effusion, visit of the breast should be included in the follow-up process.

show abstract

Utility of GATA‐3 in the work‐Up of breast adenocarcinoma and its differential diagnosis in serous effusions:

Abstract: GATA3 is a useful marker in determining the breast origin of metastatic adenocarcinoma in malignant serous effusions. Reactivity to GATA3 may indicate good prognosis. Diagn. Cytopathol. 2016;44:731-736. © 2016 Wiley Periodicals, Inc.

Cited by 15 publications

References 29 publications

Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study

Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study

EGFR TKI Combined with PD1 Inhibitor for EGFR Mutated Lung Cancer with Breast Metastasis

Almonertinib in the treatment of lung cancer with breast metastasis: a case report

Contact Info

Product

Resources

About